Abstract
Neonatal withdrawal can be difficult to treat in infants with co-exposure to opiates and gabapentin. Because maternal self-report can underestimate exposures, we evaluated the effect of universal toxicology screening for gabapentin. Identification of co-exposure to opiates and gabapentin increased after implementation of toxicology screening, with implications for improved neonatal care.
Copyright © 2019 Elsevier Inc. All rights reserved.
MeSH terms
-
Analgesics, Opioid / adverse effects
-
Excitatory Amino Acid Antagonists / adverse effects
-
Female
-
Follow-Up Studies
-
Gabapentin / adverse effects*
-
Humans
-
Incidence
-
Infant, Newborn
-
Neonatal Abstinence Syndrome / diagnosis
-
Neonatal Abstinence Syndrome / epidemiology
-
Neonatal Abstinence Syndrome / prevention & control*
-
Opiate Alkaloids / adverse effects*
-
Pregnancy
-
Prenatal Exposure Delayed Effects / diagnosis
-
Prenatal Exposure Delayed Effects / epidemiology
-
Prenatal Exposure Delayed Effects / prevention & control*
-
Retrospective Studies
-
West Virginia / epidemiology
Substances
-
Analgesics, Opioid
-
Excitatory Amino Acid Antagonists
-
Opiate Alkaloids
-
Gabapentin